Shilpa Medicare Launches First Affordable Generic Drug to treat advanced kidney Cancer

In continuation to its recent Successful Launches of Three Products in the Cancer therapy, Lenvatinib "LENSHIL® Dasatinib "DASASHIL®" and Ibrutinib "IBRUSHIL®" in India Market, Shilpa Medicare Limited today launches the Indian branded generic of Axitinib, an tyrosine kinase inhibitor drug with a brand name AXISHIL.

AXISHIL is available as 1 mg & 5 mg tablets in pack of 14's Tablets in one bottle.

AXISHIL is used to treat patients suffering from Advanced Renal Cell Carcinoma (RCC).

This novel targeted therapy attacks cancer cells without damaging normal cells, thus causing fewer side effects. There has been a significant improvement in survival ratcs in paticnts with advanced renal cancer duc to advent of this novel targeted therapy.

Currently the monthly therapy cost of innovator is approximately 1.66 Lacs and with the launch of AXISHIL, monthly cost of treatment will be reduced drastically to Rs. 14940/-.

Driving the Vision of Shilpa Medicare of "Innovating for affordable healthcare", AXISHIL is being launched to provide global quality Indian Brand with greater affordability to cancer patients. Today there are around 17,000 to 21,000 new patients in India who needs Axitinib and can be benefited by AXISHIL tablets says Mr. Sundeip Bhatia, Business Head Formulations India.

Shares of SHILPA MEDICARE LTD. was last trading in BSE at Rs.481.95 as compared to the previous close of Rs. 473.35. The total number of shares traded during the day was 9642 in over 904 trades.

The stock hit an intraday high of Rs. 498.1 and intraday low of 472.6. The net turnover during the day was Rs. 4716409.

Source : Equity Bulls

Keywords